| Kiel classification | Classification of non-Hodgkin's lymphoma into low-grade malignancy (lymphocytic, lymphoplasmacytoid, centrocytic, and centroblastic-centrocytic types) and high-grade malignancy (centroblastic, lymphoblastic of Burkitt's or convoluted cell, and immunoblastic types). Synonym: Lennert classification. (05 Mar 2000) |
|---|---|
| Lancefield classification | A serologic classification dividing haemolytic streptococci into groups (A to O) which bear a definite relationship to their sources, based upon precipitation tests depending upon group-specific substances that are carbohydrate in nature; e.g., Group A contains strains pathogenic for man; B, strains from mastitis in cows and from normal milk, including a few strains from the human throat and vagina; C, strains from various lower animals, including a number from cattle; D, strains from cheese; E, strains from certified milk; F, strains mainly from the human throat, associated with tonsillitis; G, strains from man, a few from monkeys and dogs; and H, K, and O, nonpathogenic strains from normal human respiratory tracts. (05 Mar 2000) |
| French-American-British classification | <haematology> The classification of acute myeloid leukaemia on the basis of bone marrow and peripheral blood features. M0: Acute myeloid leukaemia with minimal evidence of myeloid differentiation. M1: Acute myeloblastic leukaemia. M2: Acute myeloblastic leukaemia with differentiation. M3: Acute promyelocytic leukaemia. M4: Acute myelomonocytic leukaemia. M5: Acute monocytic leukaemia. M6: Acute erythroleukaemia. M7: Acute megakaryocytic leukaemia. Acronym: FAB (07 Apr 1998) |
| Lennert classification | Classification of non-Hodgkin's lymphoma into low-grade malignancy (lymphocytic, lymphoplasmacytoid, centrocytic, and centroblastic-centrocytic types) and high-grade malignancy (centroblastic, lymphoblastic of Burkitt's or convoluted cell, and immunoblastic types). Synonym: Lennert classification. (05 Mar 2000) |
| Lukes-Collins classification | A classification of lymphomas according to the immunologic nature of the cell of origin, based on histologic and clinical data. (05 Mar 2000) |